MENU
HELX
ETF ticker: BATS
PRICE
CHANGE
NET ASSETS

HELX stock forecast, quote, news & analysis

The investment seeks capital appreciation... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
a Summary for HELX with price predictions
Nov 10, 2026

HELX's Stochastic Oscillator is remaining in oversold zone for 2 days

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for HELX crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.

Following a +2.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where HELX advanced for three days, in 212 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

The Aroon Indicator entered an Uptrend today. In 201 of 240 cases where HELX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.

Bearish Trend Analysis

The 10-day RSI Indicator for HELX moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 24 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 75%.

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HELX as a result. In 65 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.

The Moving Average Convergence Divergence Histogram (MACD) for HELX turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 36 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

HELX moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HELX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

HELX broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.

Market Cap

The average market capitalization across the Franklin Genomic Advancements ETF (HELX) ETF is 40.29B. The market cap for tickers in the group ranges from 506.49M to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is NGNE at 506.49M.

High and low price notable news

The average weekly price growth across all stocks in the Franklin Genomic Advancements ETF (HELX) ETF was 46%. For the same ETF, the average monthly price growth was 96%, and the average quarterly price growth was 407%. ETON experienced the highest price growth at 33%, while VCYT experienced the biggest fall at -52%.

Volume

The average weekly volume growth across all stocks in the Franklin Genomic Advancements ETF (HELX) ETF was -21%. For the same stocks of the ETF, the average monthly volume growth was -24% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 55
Price Growth Rating: 42
SMR Rating: 77
Profit Risk Rating: 73
Seasonality Score: 26 (-100 ... +100)
HELX's Stochastic Oscillator is remaining in oversold zone for 2 days